Riken Immune Rejuvenation Medicine Co., Ltd. Offered by KWNA LLP - - PowerPoint PPT Presentation

Riken Immune Rejuvenation Medicine Co., Ltd.

Offered by KWNA LLP (Tokyo - USA) in association with Guoyuan Securities Co. (Hong Kong)

A unique anti-cancer immunotherapy treatment to be offered in China and Hong Kong and IPO’d in 2019

Potential regional partners include Guoyuan Securities, China Merchant Bank and China Biotech Services

Riken’s Competitive Advantage

• NK + T Therapy applied via 2 to 4 infusions
• Dendric cells injected after culture is made of patient’s own blood
• A NATURAL THERAPY WITH NO OUTSIDE DRUGS OR CHEMICALS
• iNKT (invariant natural killer T) cells activated to fight cancer
• SIMULTANEOUS NK + T ACTIVATION IS UNIQUE
• Benefits remain active for 9 months in the body
• UNIQUE LONG-LASTING BENEFITS
• NK+T Therapy can be applied with other NK therapies
• NKT OPERATES VIA A DIFFERENT MECHANIC

Regional Markets Identified

• Japan
• NKT therapy is licensed and is being applied to patients today. 81% success rate.
• China PRC and Hong Kong
• NK cell therapy is available but NKT will require regulatory approval (12 months)
• Republic of Korea
• NK cell therapy is available but NKT will require regulatory approval (9 months)
• United States
• NK cell therapy and altered T cell therapy in clinical trials stage. FDA approval some time away (36 months)
• Europe
• NK cell therapy and altered T cell therapy in clinical trials stage. Government approval some time away (36 months)

How does it work?

Infusion introduces patient’s modified dendric cell TWO TREATMENTS 1 - NK activates your natural immune system 2 - Killer T cell activates your applied immune system RESULT success ratio of 81% upon treatment to level 4 cancer patients.

Business Plan

Step 1

• HK Holding

Company formed to hold all IP

• China JV

formed and

• perational
• IPO 2019

Step 2

• Other

Regional Companies formed to file required IP and government approvals [SEED ROUND] Step 3

• Regional

Companies to offer therapy (JV’s with medical company’s)

• Pre-IPO

funding

• IPO 2020+

Step 4

• NKT

becomes a Cancer Prevention Therapy for every person with genetic pre- disposition

Conclusion

• IP Company will list in Hong Kong and IPO. Investors interested in the IPO

and subsequent rounds should contact us at:

• Kubo, Whang, Nolan and Amado LLP
• Regional JV Partners and seed capital investors are needed in each specific

region.

• Regional partners should be capable of completing all IP applications and have

strong government relationships for therapy approvals.

• Where clinical trials are required for government licensing, JV Partners should

have a proven track record of successful clinical trial management.